RNU2-1 and neoplasm: A trend toward downregulation was also observed for all other candidate tumor suppressors: RNU2-1 (p = 0.1599), SCARNA2 (p = 0.0627), SCARNA3 (p = 0.1194), and SNORD15B (p = 0.0742).